

108TH CONGRESS
1ST SESSION

H. R. 663

IN THE SENATE OF THE UNITED STATES

MARCH 13, 2003

Received; read twice and referred to the Committee on Health, Education,
Labor, and Pensions

AN ACT

To amend title IX of the Public Health Service Act to provide for the improvement of patient safety and to reduce the incidence of events that adversely affect patient safety, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

2 (a) SHORT TITLE.—This Act may be cited as the
3 “Patient Safety and Quality Improvement Act”.

4 (b) TABLE OF CONTENTS.—The table of contents for
5 this Act is as follows:

Sec. 1. Short title; table of contents.

Sec. 2. Findings and purposes.

TITLE I—PATIENT SAFETY AND QUALITY IMPROVEMENT

Sec. 101. Amendments to Public Health Service Act.

Sec. 102. Promoting the diffusion and interoperability of information technology systems involved with health care delivery.

Sec. 103. Required use of product identification technology.

Sec. 104. Grants for electronic prescription programs.

Sec. 105. Grants to hospitals and other health care providers for information technologies.

Sec. 106. Authorization of appropriations for grants under sections 104 and 105.

TITLE II—MEDICAL INFORMATION TECHNOLOGY ADVISORY BOARD.

Sec. 201. Medical Information Technology Advisory Board.

6 **SEC. 2. FINDINGS AND PURPOSES.**

7 (a) FINDINGS.—The Congress finds as follows:

8 (1) In 1999, the Institute of Medicine released
9 a report entitled “To Err Is Human” that described
10 medical errors as the 8th leading cause of death in
11 the United States, with as many as 98,000 people
12 dying as a result of medical errors each year.

13 (2) To address these deaths and injuries due to
14 medical errors, the health care system must identify
15 and learn from such errors so that systems of care
16 can be improved.

1 (3) Myriad public and private patient safety ini-
2 tiatives have begun. The Quality Interagency Coordi-
3 nation Task Force has recommended steps to im-
4 prove patient safety that may be taken by each Fed-
5 eral agency involved in health care and activities re-
6 lating to these steps are ongoing.

7 (4) The Department of Health and Human
8 Services has initiated several patient safety projects.
9 The Joint Commission on Accreditation of
10 Healthcare Organizations issued a patient safety
11 standard that went into effect on July 1, 2001, and
12 the peer review organizations are conducting ongoing
13 studies of clinical performance measurement of care
14 delivered to beneficiaries under the medicare pro-
15 gram under title XVIII of the Social Security Act.

16 (5) Several steps can be taken now to improve
17 patient safety. For example, according to the Cen-
18 ters for Disease Control and Prevention, hand wash-
19 ing is the single most important means of preventing
20 the spread of infection. Repeated studies indicate
21 that lack of or improper hand washing still contrib-
22 utes significantly to disease transmission in health
23 care settings. Working with experts from the private
24 sector, the Centers for Disease Control and Preven-
25 tion has drafted “Guidelines for Hand Hygiene in

1 Healthcare Settings” setting forth recommendations
2 to promote improved hand hygiene practices and re-
3 duce transmission of pathogenic microorganisms to
4 patients and personnel in health care settings.

5 (6) According to the Centers for Disease Con-
6 trol and Prevention, nosocomial infections affect ap-
7 proximately 2 million patients annually in acute care
8 facilities in the United States at an estimated direct
9 patient care cost of approximately \$3.5 billion each
10 year.

11 (7) The Congress encourages the continuation
12 and acceleration of private sector efforts to take im-
13 mediate steps to improve patient safety and recog-
14 nizes the need for action in the public sector to com-
15 plement these efforts.

16 (8) The research on patient safety unequivocally
17 calls for a learning environment, where pro-
18 viders will feel safe to report health care errors, in
19 order to improve patient safety.

20 (9) Voluntary data gathering systems are more
21 supportive than mandatory systems in creating the
22 learning environment referred to in paragraph (8) as
23 stated in the Institute of Medicine’s report.

24 (10) Promising patient safety reporting systems
25 have been established throughout the United States,

1 and the best ways to structure and use these sys-
2 tems are currently being determined, largely through
3 projects funded by the Agency for Healthcare Re-
4 search and Quality.

5 (11) Many organizations currently collecting
6 patient safety information have expressed a need for
7 protections that will allow them to review protected
8 information so that they may collaborate in the de-
9 velopment and implementation of patient safety im-
10 provement strategies. Currently, the State peer re-
11 view protections provide inadequate conditions to
12 allow the sharing of information to promote patient
13 safety.

14 (12) In 2001, the Institute of Medicine released
15 a report entitled “Crossing the Quality Chasm” that
16 found that the United States health care system
17 does not consistently deliver high-quality care to pa-
18 tients.

19 (b) PURPOSES.—The purposes of this Act are—

20 (1) to encourage a culture of safety and quality
21 in the United States health care system by providing
22 for a health care errors reporting system that both
23 protects information and improves patient safety
24 and quality of health care; and

1 (2) to ensure accountability by raising stand-
 2 ards and expectations for continuous quality im-
 3 provements in patient safety through the actions of
 4 the Secretary of Health and Human Services.

5 **TITLE I—PATIENT SAFETY AND**
 6 **QUALITY IMPROVEMENT**

7 **SEC. 101. AMENDMENTS TO PUBLIC HEALTH SERVICE ACT.**

8 (a) IN GENERAL.—Title IX of the Public Health
 9 Service Act (42 U.S.C. 299 et seq.) is amended—

10 (1) in section 912(c), by inserting “, in accord-
 11 ance with part C,” after “The Director shall”;

12 (2) by redesignating part C as part D;

13 (3) by redesignating sections 921 through 928,
 14 as sections 931 through 938, respectively;

15 (4) in section 938(1) (as so redesignated), by
 16 striking “921” and inserting “931”; and

17 (5) by inserting after part B the following:

18 **“PART C—PATIENT SAFETY IMPROVEMENT**

19 **“SEC. 921. DEFINITIONS.**

20 “In this part:

21 “(1) IDENTIFIABLE INFORMATION.—The term
 22 ‘identifiable information’ means information that is
 23 presented in a form and manner that allows the
 24 identification of any provider, patient, or reporter of
 25 patient safety work product. With respect to pa-

1 tients, such information includes any individually
2 identifiable health information as that term is de-
3 fined in the regulations promulgated pursuant to
4 section 264(c) of the Health Insurance Portability
5 and Accountability Act of 1996 (Public Law 104–
6 191; 110 Stat. 2033).

7 “(2) NONIDENTIFIABLE INFORMATION.—The
8 term ‘nonidentifiable information’ means informa-
9 tion that is presented in a form and manner that
10 prevents the identification of any provider, patient,
11 or reporter of patient safety work product. With re-
12 spect to patients, such information must be de-iden-
13 tified consistent with the regulations promulgated
14 pursuant to section 264(c) of the Health Insurance
15 Portability and Accountability Act of 1996 (Public
16 Law 104–191; 110 Stat. 2033).

17 “(3) PATIENT SAFETY EVALUATION SYSTEM.—
18 The term ‘patient safety evaluation system’ means a
19 process that involves the collection, management, or
20 analysis of information for submission to or by a pa-
21 tient safety organization.

22 “(4) PATIENT SAFETY ORGANIZATION.—The
23 term ‘patient safety organization’ means a private or
24 public organization or component thereof that is cer-
25 tified, through a process to be determined by the

1 Secretary under section 925, to perform each of the
2 following activities:

3 “(A) The conduct, as the organization or
4 component’s primary activity, of efforts to im-
5 prove patient safety and the quality of health
6 care delivery.

7 “(B) The collection and analysis of patient
8 safety work product that is submitted by pro-
9 viders.

10 “(C) The development and dissemination
11 of evidence-based information to providers with
12 respect to improving patient safety, such as rec-
13 ommendations, protocols, or information re-
14 garding best practices.

15 “(D) The utilization of patient safety work
16 product to carry out activities limited to those
17 described under this paragraph and for the pur-
18 poses of encouraging a culture of safety and of
19 providing direct feedback and assistance to pro-
20 viders to effectively minimize patient risk.

21 “(E) The maintenance of confidentiality
22 with respect to identifiable information.

23 “(F) The provision of appropriate security
24 measures with respect to patient safety work
25 product.

1 “(G) The submission of nonidentifiable in-
2 formation to the Agency consistent with stand-
3 ards established by the Secretary under section
4 923(b) for any National Patient Safety Data-
5 base.

6 “(5) PATIENT SAFETY WORK PRODUCT.—

7 “(A) The term ‘patient safety work prod-
8 uct’ means any document or communication
9 (including any information, report, record,
10 memorandum, analysis, deliberative work, state-
11 ment, or root cause analysis) that—

12 “(i) except as provided in subpara-
13 graph (B), is developed by a provider for
14 the purpose of reporting to a patient safety
15 organization, and is reported to a patient
16 safety organization;

17 “(ii) is created by a patient safety or-
18 ganization; or

19 “(iii) would reveal the deliberations or
20 analytic process of a patient safety evalua-
21 tion system (as defined in paragraph (3)).

22 “(B)(i) Patient safety work product de-
23 scribed in subparagraph (A)(i)—

24 “(I) does not include any separate in-
25 formation described in clause (ii); and

1 “(II) shall not be construed to include
2 such separate information merely by rea-
3 son of inclusion of a copy of the document
4 or communication involved in a submission
5 to, or the fact of submission of such a copy
6 to, a patient safety organization.

7 “(ii) Separate information described in this
8 clause is a document or communication (includ-
9 ing a patient’s medical record or any other pa-
10 tient or hospital record) that is developed or
11 maintained, or exists, separately from any pa-
12 tient safety evaluation system.

13 “(C) Information available from sources
14 other than a patient safety work product under
15 this section may be discovered or admitted in a
16 civil or administrative proceeding, if discover-
17 able or admissible under applicable law.

18 “(6) PROVIDER.—The term ‘provider’ means—

19 “(A) an individual or entity licensed or
20 otherwise authorized under State law to provide
21 health care services, including—

22 “(i) a hospital, nursing facility, com-
23 prehensive outpatient rehabilitation facil-
24 ity, home health agency, and hospice pro-
25 gram;

1 “(ii) a physician, physician assistant,
2 nurse practitioner, clinical nurse specialist,
3 certified nurse midwife, nurse anesthetist,
4 psychologist, certified social worker, reg-
5 istered dietitian or nutrition professional,
6 physical or occupational therapist, or other
7 individual health care practitioner;

8 “(iii) a pharmacist; and

9 “(iv) a renal dialysis facility, ambula-
10 tory surgical center, pharmacy, physician
11 or health care practitioner’s office, long-
12 term care facility, behavioral health resi-
13 dential treatment facility, clinical labora-
14 tory, or community health center; or

15 “(B) any other person or entity specified
16 in regulations by the Secretary after public no-
17 tice and comment.

18 **“SEC. 922. PRIVILEGE FOR PATIENT SAFETY WORK PROD-**
19 **UCT.**

20 “(a) PRIVILEGE.—Notwithstanding any other provi-
21 sion of law and subject to subsection (c), patient safety
22 work product shall not be—

23 “(1) subject to a civil or administrative sub-
24 poena or order;

1 “(2) subject to discovery in connection with a
2 civil or administrative proceeding;

3 “(3) subject to disclosure pursuant to section
4 552 of title 5, United States Code (commonly known
5 as the Freedom of Information Act), or any other
6 similar Federal or State law;

7 “(4) required to be admitted as evidence or oth-
8 erwise disclosed in any State or Federal civil or ad-
9 ministrative proceeding; or

10 “(5) if the patient safety work product is identi-
11 fiable information and is received by a national ac-
12 creditation organization in its capacity as a patient
13 safety organization—

14 “(A) used by a national accreditation orga-
15 nization in an accreditation action against the
16 provider that reported the information;

17 “(B) shared by such organization with its
18 survey team; or

19 “(C) required as a condition of accredita-
20 tion by a national accreditation association.

21 “(b) REPORTER PROTECTION.—

22 “(1) IN GENERAL.—A provider may not use
23 against an individual in an adverse employment ac-
24 tion described in paragraph (2) the fact that the in-
25 dividual in good faith reported information—

1 “(A) to the provider with the intention of
2 having the information reported to a patient
3 safety organization; or

4 “(B) directly to a patient safety organiza-
5 tion.

6 “(2) ADVERSE EMPLOYMENT ACTION.—For
7 purposes of this subsection, an ‘adverse employment
8 action’ includes—

9 “(A) the failure to promote an individual
10 or provide any other employment-related benefit
11 for which the individual would otherwise be eli-
12 gible;

13 “(B) an adverse evaluation or decision
14 made in relation to accreditation, certification,
15 credentialing, or licensing of the individual; and

16 “(C) a personnel action that is adverse to
17 the individual concerned.

18 “(3) REMEDIES.—Any provider that violates
19 this subsection shall be subject to a civil monetary
20 penalty of not more than \$20,000 for each such vio-
21 lation involved. Such penalty shall be imposed and
22 collected in the same manner as civil money pen-
23 alties under subsection (a) of section 1128A of the
24 Social Security Act are imposed and collected.

1 “(c) DISCLOSURES.—Nothing in this section pro-
2 hibits any of the following disclosures:

3 “(1) Voluntary disclosure of nonidentifiable in-
4 formation.

5 “(2) Voluntary disclosure of identifiable infor-
6 mation by a provider or patient safety organization,
7 if such disclosure—

8 “(A) is authorized by the provider for the
9 purposes of improving quality and safety;

10 “(B) is to an entity or person subject to
11 the requirements of section 264(c) of the
12 Health Insurance Portability and Accountability
13 Act of 1996 (Public Law 104–191; 110 Stat.
14 2033), or any regulation promulgated under
15 such section; and

16 “(C) is not in conflict with such section or
17 any regulation promulgated under such section.

18 “(3) Disclosure as required by law by a pro-
19 vider to the Food and Drug Administration, or on
20 a voluntary basis by a provider to a federally estab-
21 lished patient safety program, with respect to an Ad-
22 ministration-regulated product or activity for which
23 that entity has responsibility, for the purposes of ac-
24 tivities related to the quality, safety, or effectiveness
25 of such Administration-regulated product or activity.

1 “(4) Disclosures of patient safety work product
2 in accordance with this part by a provider to a pa-
3 tient safety organization.

4 “(d) EFFECT OF TRANSFER, DISCLOSURE.—The fol-
5 lowing shall not be treated as a waiver of any privilege
6 or protection established under this part:

7 “(1) The transfer of any patient safety work
8 product between a provider and a patient safety or-
9 ganization.

10 “(2) Disclosure of patient safety work product
11 as described in subsection (c).

12 “(3) The unauthorized disclosure of patient
13 safety work product.

14 “(e) PENALTY.—

15 “(1) PROHIBITION.—Except as provided in this
16 part, and subject to paragraphs (2) and (4), it shall
17 be unlawful for any person to disclose patient safety
18 work product in violation of this section, if such dis-
19 closure constitutes a negligent or knowing breach of
20 confidentiality.

21 “(2) RELATION TO HIPAA.—The penalty under
22 paragraph (3) for a disclosure in violation of para-
23 graph (1) does not apply if the person would be sub-
24 ject to a penalty under section 264(c) of the Health
25 Insurance Portability and Accountability Act of

1 1996 (Public Law 104–191; 110 Stat. 2033), or any
2 regulation promulgated under such section, for the
3 same disclosure.

4 “(3) AMOUNT.—Any person who violates para-
5 graph (1) shall be subject to a civil monetary penalty
6 of not more than \$10,000 for each such violation in-
7 volved. Such penalty shall be imposed and collected
8 in the same manner as civil money penalties under
9 subsection (a) of section 1128A of the Social Secu-
10 rity Act are imposed and collected.

11 “(4) SUBSEQUENT DISCLOSURE.—Paragraph
12 (1) applies only to the first person that breaches
13 confidentiality with respect to particular patient
14 safety work product.

15 “(f) RELATION TO HIPAA.—

16 “(1) IN GENERAL.—For purposes of applying
17 the regulations promulgated pursuant to section
18 264(c) of the Health Insurance Portability and Ac-
19 countability Act of 1996 (Public Law 104–191; 110
20 Stat. 2033)—

21 “(A) patient safety organizations shall be
22 treated as business associates; and

23 “(B) activities of such organizations de-
24 scribed in section 921(4) in relation to a pro-

1 vider are deemed to be health care operations
2 (as defined in such regulations) of the provider.

3 “(2) RULE OF CONSTRUCTION.—Nothing in
4 this section shall be construed to alter or affect the
5 implementation of such regulations or such section
6 264(c).

7 “(g) NO LIMITATION OF OTHER PRIVILEGES.—
8 Nothing in this section shall be construed to affect privi-
9 leges, including peer review and confidentiality protec-
10 tions, that are otherwise available under Federal or State
11 laws.

12 “(h) NO LIMITATION ON CONTRACTS.—Nothing in
13 this section shall be construed to limit the power of a pro-
14 vider and a patient safety organization, or a patient safety
15 organization and the Agency or any National Patient
16 Safety Database, consistent with the provisions of this Act
17 and other applicable law, to enter into a contract requiring
18 greater confidentiality or delegating authority to make an
19 authorized disclosure.

20 “(i) RELATION TO STATE REPORTING REQUIRE-
21 MENTS.—Nothing in this part shall be construed as pre-
22 empting or otherwise affecting any State law requiring a
23 provider to report information, including information de-
24 scribed in section 921(5)(B), that is not patient safety
25 work product.

1 “(j) CONTINUATION OF PRIVILEGE.—Patient safety
2 work product of an organization that is certified as a pa-
3 tient safety organization shall continue to be privileged
4 and confidential, in accordance with this section, if the or-
5 ganization’s certification is terminated or revoked or if the
6 organization otherwise ceases to qualify as a patient safety
7 organization.

8 “(k) REPORTS ON STRATEGIES TO IMPROVE PA-
9 TIENT SAFETY.—

10 “(1) DRAFT REPORT.—Not later than the date
11 that is 18 months after any National Patient Safety
12 Database is operational, the Secretary, in consulta-
13 tion with the Director, shall prepare a draft report
14 on effective strategies for reducing medical errors
15 and increasing patient safety. The draft report shall
16 include any measure determined appropriate by the
17 Secretary to encourage the appropriate use of such
18 strategies, including use in any federally funded pro-
19 grams. The Secretary shall make the draft report
20 available for public comment and submit the draft
21 report to the Institute of Medicine for review.

22 “(2) FINAL REPORT.—Not later than 1 year
23 after the date described in paragraph (1), the Sec-
24 retary shall submit a final report to the Congress
25 that includes, in an appendix, any findings by the

1 Institute of Medicine concerning research on the
2 strategies discussed in the draft report and any
3 modifications made by the Secretary based on such
4 findings.

5 **“SEC. 923. NATIONAL PATIENT SAFETY DATABASE.**

6 “(a) AUTHORITY.—

7 “(1) IN GENERAL.—In conducting activities
8 under this part, the Secretary shall provide for the
9 establishment and maintenance of a database to re-
10 ceive relevant nonidentifiable patient safety work
11 product, and may designate entities to collect rel-
12 evant nonidentifiable patient safety work product
13 that is voluntarily reported by patient safety organi-
14 zations upon the request of the Secretary. Any data-
15 base established or designated under this paragraph
16 may be referred to as a ‘National Patient Safety
17 Database’.

18 “(2) USE OF INFORMATION.—Information re-
19 ported to any National Patient Safety Database
20 shall be used to analyze national and regional statis-
21 tics, including trends and patterns of health care er-
22 rors. The information resulting from such analyses
23 may be included in the annual quality reports pre-
24 pared under section 913(b)(2).

1 “(3) ADVISORY ROLE.—The Secretary shall
2 provide scientific support to patient safety organiza-
3 tions, including the dissemination of methodologies
4 and evidence-based information related to root
5 causes and quality improvement.

6 “(b) STANDARDS.—In establishing or designating a
7 database under subsection (a)(1), the Secretary shall, in
8 consultation with representatives of patient safety organi-
9 zations, the provider community, and the health informa-
10 tion technology industry, determine common formats for
11 the voluntary reporting of nonidentifiable patient safety
12 work product, including necessary elements, common and
13 consistent definitions, and a standardized computer inter-
14 face for the processing of the work product. To the extent
15 practicable, such standards shall be consistent with the
16 administrative simplification provisions of part C of title
17 XI of the Social Security Act.

18 “(c) CERTAIN METHODOLOGIES FOR COLLECTION.—
19 The Secretary shall ensure that the methodologies for the
20 collection of nonidentifiable patient safety work product
21 for any National Patient Safety Database include the
22 methodologies developed or recommended by the Patient
23 Safety Task Force of the Department of Health and
24 Human Services.

1 “(d) FACILITATION OF INFORMATION EXCHANGE.—
2 To the extent practicable, the Secretary may facilitate the
3 direct link of information between providers and patient
4 safety organizations and between patient safety organiza-
5 tions and any National Patient Safety Database.

6 “(e) RESTRICTION ON TRANSFER.—Only nonidentifi-
7 able information may be transferred to any National Pa-
8 tient Safety Database.

9 **“SEC. 924. TECHNICAL ASSISTANCE.**

10 “(a) IN GENERAL.—The Secretary, acting through
11 the Director, may—

12 “(1) provide technical assistance to patient
13 safety organizations, and to States with reporting
14 systems for health care errors; and

15 “(2) provide guidance on the type of data to be
16 voluntarily submitted to any National Patient Safety
17 Database.

18 “(b) ANNUAL MEETINGS.—Assistance provided
19 under subsection (a) may include annual meetings for pa-
20 tient safety organizations to discuss methodology, commu-
21 nication, information collection, or privacy concerns.

22 **“SEC. 925. CERTIFICATION OF PATIENT SAFETY ORGANIZA-**
23 **TIONS.**

24 “(a) IN GENERAL.—Not later than 6 months after
25 the date of enactment of the Patient Safety and Quality

1 Improvement Act, the Secretary shall establish a process
2 for certifying patient safety organizations.

3 “(b) PROCESS.—The process established under sub-
4 section (a) shall include the following:

5 “(1) Certification of patient safety organiza-
6 tions by the Secretary or by such other national or
7 State governmental organizations as the Secretary
8 determines appropriate.

9 “(2) If the Secretary allows other governmental
10 organizations to certify patient safety organizations
11 under paragraph (1), the Secretary shall establish a
12 process for approving such organizations. Any such
13 approved organization shall conduct certifications
14 and reviews in accordance with this section.

15 “(3) A review of each certification under para-
16 graph (1) (including a review of compliance with
17 each criterion in this section and any related imple-
18 menting standards as determined by the Secretary
19 through rulemaking) not less often than every 3
20 years, as determined by the Secretary.

21 “(4) Revocation of any such certification by the
22 Secretary or other such governmental organization
23 that issued the certification, upon a showing of
24 cause.

1 “(c) CRITERIA.—A patient safety organization must
2 meet the following criteria as conditions of certification:

3 “(1) The mission of the patient safety organiza-
4 tion is to conduct activities that are to improve pa-
5 tient safety and the quality of health care delivery
6 and is not in conflict of interest with the providers
7 that contract with the patient safety organization.

8 “(2) The patient safety organization has appro-
9 priately qualified staff, including licensed or certified
10 medical professionals.

11 “(3) The patient safety organization, within any
12 2 year period, contracts with more than 1 provider
13 for the purpose of receiving and reviewing patient
14 safety work product.

15 “(4) The patient safety organization is not a
16 component of a health insurer or other entity that
17 offers a group health plan or health insurance cov-
18 erage.

19 “(5) The patient safety organization is man-
20 aged, controlled, and operated independently from
21 any provider that contracts with the patient safety
22 organization for reporting patient safety work prod-
23 uct.

24 “(6) To the extent practical and appropriate,
25 the patient safety organization collects patient safety

1 work product from providers in a standardized man-
2 ner that permits valid comparisons of similar cases
3 among similar providers.

4 “(d) ADDITIONAL CRITERIA FOR COMPONENT ORGA-
5 NIZATIONS.—If a patient safety organization is a compo-
6 nent of another organization, the patient safety organiza-
7 tion must, in addition to meeting the criteria described
8 in subsection (c), meet the following criteria as conditions
9 of certification:

10 “(1) The patient safety organization maintains
11 patient safety work product separately from the rest
12 of the organization, and establishes appropriate se-
13 curity measures to maintain the confidentiality of
14 the patient safety work product.

15 “(2) The patient safety organization does not
16 make an unauthorized disclosure under this Act of
17 patient safety work product to the rest of the orga-
18 nization in breach of confidentiality.

19 “(3) The mission of the patient safety organiza-
20 tion does not create a conflict of interest with the
21 rest of the organization.”.

22 (b) AUTHORIZATION OF APPROPRIATIONS.—Section
23 937 of the Public Health Service Act (as redesignated by
24 subsection (a)) is amended by adding at the end the fol-
25 lowing:

1 “(e) PATIENT SAFETY AND QUALITY IMPROVE-
2 MENT.—For the purpose of carrying out part C, there are
3 authorized to be appropriated such sums as may be nec-
4 essary for each of the fiscal years 2004 through 2008.”.

5 **SEC. 102. PROMOTING THE DIFFUSION AND INTEROPER-**
6 **ABILITY OF INFORMATION TECHNOLOGY SYS-**
7 **TEMS INVOLVED WITH HEALTH CARE DELIV-**
8 **ERY.**

9 (a) VOLUNTARY STANDARDS.—

10 (1) IN GENERAL.—Not later than 18 months
11 after the date of the enactment of this Act, the Sec-
12 retary of Health and Human Services (in this sec-
13 tion referred to as the “Secretary”) shall—

14 (A) develop or adopt voluntary national
15 standards that promote the interoperability of
16 information technology systems involved with
17 health care delivery, including but not limited to
18 computerized physician order entry;

19 (B) in developing or adopting such stand-
20 ards, take into account—

21 (i) the ability of such systems to cap-
22 ture and aggregate clinically specific data
23 to enable evidence-based medicine and
24 other applications that promote the elec-

1 tronic exchange of patient medical record
2 information; and

3 (ii) the cost that meeting such stand-
4 ards would have on providing health care
5 in the United States and the increased effi-
6 ciencies in providing such care achieved
7 under the standards;

8 (C) in developing or adopting such stand-
9 ards and to the extent practicable, test the effi-
10 cacy, usability, and scalability of proposed inter-
11 operability standards within a variety of clinical
12 settings, including an urban academic medical
13 center, a rural hospital, a community health
14 center, and a community hospital; and

15 (D) submit a report to the Congress con-
16 taining recommendations on such standards.

17 (2) CONSULTATION.—In developing or adopting
18 standards under paragraph (1)(A), the Secretary
19 shall consider the recommendations of the National
20 Committee on Vital Health Statistics for the stand-
21 ardization of message formatting, coding, and vocab-
22 ulary for interoperability of information technology
23 systems involved with health care delivery. The Sec-
24 retary shall consult with representatives of the
25 health information technology industry and the pro-

1 vider community who are involved with the develop-
2 ment of interoperability standards.

3 (b) UPDATES.—The Secretary shall provide for the
4 ongoing review and periodic updating of the standards de-
5 veloped under subsection (a).

6 **SEC. 103. REQUIRED USE OF PRODUCT IDENTIFICATION**
7 **TECHNOLOGY.**

8 The Federal Food, Drug, and Cosmetic Act (21
9 U.S.C. 301 et seq.) is amended—

10 (1) in section 502, by adding at the end the fol-
11 lowing:

12 “(w) If it is a drug or biological product, unless it
13 includes a unique product identifier for the drug or bio-
14 logical product as required by regulations under section
15 510(q).”; and

16 (2) in section 510, by adding at the end the fol-
17 lowing:

18 “(q)(1) The Secretary shall issue, and may periodi-
19 cally revise, regulations requiring the manufacturer of any
20 drug or biological product that is subject to regulation by
21 the Food and Drug Administration, or the packager or
22 labeler of a drug or biological product that is subject to
23 regulation by the Food and Drug Administration, to in-
24 clude a unique product identifier on the packaging of the
25 drug or biological product.

1 “(2) For purposes of this subsection, the term
2 ‘unique product identifier’ means an identification that—

3 “(A) is affixed by the manufacturer, labeler, or
4 packager to each drug or biological product de-
5 scribed in paragraph (1) at each packaging level;

6 “(B) uniquely identifies the item and meets the
7 standards required by this section; and

8 “(C) can be read by a scanning device or other
9 technology acceptable to the Secretary.

10 “(3) A unique product identifier required by regula-
11 tions issued or revised under paragraph (1) shall be based
12 on—

13 “(A) the National Drug Code maintained by
14 the Food and Drug Administration;

15 “(B) commercially accepted standards estab-
16 lished by organizations that are accredited by the
17 American National Standards Institute, such as the
18 Health Industry Business Communication Council or
19 the Uniform Code Council; or

20 “(C) other identification formats that the Sec-
21 retary deems appropriate.

22 “(4) The Secretary may, at the Secretary’s discre-
23 tion, waive the requirements of this section, or add addi-
24 tional provisions that are necessary to safeguard the pub-
25 lic health.”.

1 **SEC. 104. GRANTS FOR ELECTRONIC PRESCRIPTION PRO-**
2 **GRAMS.**

3 (a) GRANTS.—

4 (1) IN GENERAL.—The Secretary of Health and
5 Human Services (in this section referred to as the
6 “Secretary”) may make grants to qualified practi-
7 tioners for the purpose of establishing electronic pre-
8 scription programs.

9 (2) MATCHING FUNDS.—

10 (A) IN GENERAL.—With respect to the
11 costs of establishing an electronic prescription
12 program, a condition for the receipt of a grant
13 under paragraph (1) is that the qualified practi-
14 tioner involved agree to make available (directly
15 or through donations from public or private en-
16 tities) non-Federal contributions toward such
17 costs in an amount that is not less than 50 per-
18 cent of such costs.

19 (B) DETERMINATION OF AMOUNT CON-
20 TRIBUTED.—Non-Federal contributions re-
21 quired in subparagraph (A) may be in cash or
22 in kind, fairly evaluated, including equipment or
23 services. Amounts provided by the Federal Gov-
24 ernment, or services assisted or subsidized to
25 any significant extent by the Federal Govern-

1 ment, may not be included in determining the
2 amount of such non-Federal contributions.

3 (b) STUDY.—

4 (1) IN GENERAL.—The Secretary, acting
5 through the Director of the Agency for Healthcare
6 Research and Quality, shall support a study to as-
7 sess existing scientific evidence regarding the effec-
8 tiveness and cost-effectiveness of the use of elec-
9 tronic prescription programs intended to improve the
10 efficiency of prescription ordering and the safe and
11 effective use of prescription drugs. The study shall
12 address the following:

13 (A) The ability of such programs to reduce
14 medical errors and improve the quality and
15 safety of patient care.

16 (B) The impact of the use of such pro-
17 grams on physicians, pharmacists, and patients,
18 including such factors as direct and indirect
19 costs, changes in productivity, and satisfaction.

20 (C) The effectiveness of strategies for over-
21 coming barriers to the use of electronic pre-
22 scription programs.

23 (2) REPORT.—The Secretary shall ensure that,
24 not later than 18 months after the date of the enact-
25 ment of this Act, a report containing the findings of

1 the study under paragraph (1) is submitted to the
2 appropriate committees of the Congress.

3 (3) DISSEMINATION OF FINDINGS.—The Sec-
4 retary shall disseminate the findings of the study
5 under paragraph (1) to appropriate public and pri-
6 vate entities.

7 (c) DEVELOPMENT OF MODEL.—The Secretary, act-
8 ing through the Director of the Agency for Healthcare Re-
9 search and Quality, may develop an Internet-based mathe-
10 matical model that simulates the cost and effectiveness of
11 electronic prescription programs for qualified practi-
12 tioners. The model may be designed to allow qualified
13 practitioners to estimate, through an interactive interface,
14 the impact of electronic prescribing on their practices, in-
15 cluding the reduction in drug-related health care errors.

16 (d) DEFINITIONS.—For purposes of this section:

17 (1) The term “electronic prescription pro-
18 gram”—

19 (A) means a program for the electronic
20 submission and processing of prescriptions; and

21 (B) includes the hardware (including com-
22 puters and other electronic devices) and soft-
23 ware programs for the electronic submission of
24 prescriptions to pharmacies, the processing of

1 such submissions by pharmacies, and decision-
2 support programs.

3 (2) The term “qualified practitioner” means a
4 practitioner licensed by law to administer or dis-
5 pense prescription drugs.

6 **SEC. 105. GRANTS TO HOSPITALS AND OTHER HEALTH**
7 **CARE PROVIDERS FOR INFORMATION TECH-**
8 **NOLOGIES.**

9 (a) IN GENERAL.—The Secretary of Health and
10 Human Services (in this section referred to as the “Sec-
11 retary”) shall make grants to hospitals and other health
12 care providers (but not more than 1 grant to any 1 hos-
13 pital or provider) to pay the costs of acquiring or imple-
14 menting information technologies whose purposes are—

15 (1) to improve quality of care and patient safe-
16 ty; and

17 (2) to reduce adverse events and health care
18 complications resulting from medication errors.

19 (b) SPECIAL CONSIDERATION.—In making grants
20 under subsection (a), the Secretary shall give special con-
21 sideration to applicants who seek to promote the following:

22 (1) Interoperability across hospital services or
23 departments using standards developed or adopted
24 by the Secretary under section 102.

1 (2) Electronic communication of patient data
2 across the spectrum of health care delivery.

3 (3) Computerized physician order entry or bar
4 coding applications.

5 (4) Electronic communication of patient data in
6 hospitals that provide services to underserved or low-
7 income populations.

8 (5) Improved clinical decisionmaking through
9 acquisition and implementation of decision-support
10 technologies.

11 (c) CERTAIN GRANT CONDITIONS.—A condition for
12 the receipt of a grant under subsection (a) is that the ap-
13 plicant involved meet the following requirements:

14 (1) The applicant agrees to carry out a pro-
15 gram to measure, analyze, and report patient safety
16 and medical errors at the hospital or other health
17 care provider involved, to submit to the Secretary a
18 description of the methodology that will be used, and
19 to have such program in effect as soon as prac-
20 ticable after the application for the grant is ap-
21 proved, without regard to whether information tech-
22 nologies under the grant have been implemented.

23 (2) The applicant has arranged for an evalua-
24 tion that addresses the effectiveness and cost-effec-
25 tiveness of the information technology for which the

1 grant is provided and its impact on the quality and
2 safety of patient care, submitted the evaluation plan
3 to the Secretary, and received approval from the
4 Secretary of the applicant's methodology.

5 (3) The applicant has or is developing a patient
6 safety evaluation system (as that term is defined in
7 section 921 of the Public Health Service Act (as
8 amended by section 101)) for reporting health care
9 errors to a patient safety organization.

10 (4) The applicant agrees to provide the Sec-
11 retary with such information as the Secretary may
12 require regarding the use of funds under this pro-
13 gram or its impact.

14 (5) The applicant provides assurances satisfac-
15 tory to the Secretary that any information tech-
16 nology planned, acquired, or implemented with grant
17 funds under this section will be part of an informa-
18 tion program that—

19 (A) carries out the purposes described in
20 subsection (a); and

21 (B) is comprehensive or will be expanded
22 to become comprehensive, regardless of whether
23 Federal assistance is available for such expan-
24 sion.

1 (d) TECHNICAL ASSISTANCE TO GRANTEES.—The
2 Secretary, acting through the Director of the Agency for
3 Healthcare Research and Quality, shall provide technical
4 assistance to applicants and grantees to ensure the appro-
5 priate evaluation of the information technologies for which
6 grants are awarded under this section, such as—

7 (1) reviewing and providing technical assistance
8 on the applicant’s proposed evaluation;

9 (2) developing mechanisms to ensure ongoing
10 communications between grantees and evaluators to
11 facilitate the identification and resolution of prob-
12 lems as they arise, ensure mutual learning, and pro-
13 mote the rapid dissemination of information;

14 (3) reviewing the interim and final reports re-
15 quired under subsection (e); and

16 (4) disseminating evidence-based information in
17 interim and final reports to patient safety organiza-
18 tions, as appropriate.

19 (e) EVALUATION REPORTS BY GRANTEE.—A condi-
20 tion for the receipt of a grant under subsection (a) is that
21 the applicant agree to submit an interim and a final report
22 to the Secretary in accordance with this subsection.

23 (1) INTERIM REPORT.—Not later than 1 year
24 after the implementation of information technologies
25 under the grant is completed, the applicant will sub-

1 mit an interim report to the Secretary describing the
2 initial effectiveness of such technologies in carrying
3 out the purposes described in subsection (a).

4 (2) FINAL REPORT.—Not later than 3 years
5 after the implementation of information technologies
6 under the grant is completed, the applicant will sub-
7 mit a final report to the Secretary describing the ef-
8 fectiveness and cost-effectiveness of such tech-
9 nologies and addressing other issues determined to
10 be important in carrying out the purposes described
11 in subsection (a).

12 (3) RELATION TO DISBURSEMENT OF GRANT.—
13 In disbursing a grant under subsection (a), the Sec-
14 retary shall withhold $\frac{1}{3}$ of the grant until the grant-
15 ee submits to the Secretary the report required in
16 paragraph (1).

17 (f) REPORTS BY SECRETARY.—

18 (1) INTERIM REPORTS.—

19 (A) IN GENERAL.—Through the fiscal year
20 preceding the fiscal year in which the final re-
21 port under paragraph (2) is prepared, the Sec-
22 retary shall submit to the Committee on Energy
23 and Commerce of the House of Representatives
24 and the Committee on Health, Education,
25 Labor, and Pensions of the Senate periodic re-

1 ports on the grant program under subsection
2 (a). Such reports shall be submitted not less
3 frequently than once each fiscal year, beginning
4 with fiscal year 2004.

5 (B) CONTENTS.—A report under subpara-
6 graph (A) shall include information on—

7 (i) the number of grants made;

8 (ii) the nature of the projects for
9 which funding is provided under the grant
10 program;

11 (iii) the geographic distribution of
12 grant recipients; and

13 (iv) such other matters as the Sec-
14 retary determines appropriate.

15 (2) FINAL REPORT.—Not later than 180 days
16 after the date on which the last of the reports is due
17 under subsection (e)(2), the Secretary shall submit
18 a final report to the committees referred to in para-
19 graph (1)(A) on the grant program under subsection
20 (a), together with such recommendations for legisla-
21 tion and administrative action as the Secretary de-
22 termines appropriate.

23 (g) DEFINITIONS.—For purposes of this section:

1 (1) The term “costs”, with respect to informa-
2 tion technologies referred to in subsection (a), in-
3 cludes total expenditures incurred for—

4 (A) purchasing, leasing, and installing
5 computer software and hardware, including
6 hand-held computer technologies;

7 (B) making improvements to existing com-
8 puter software and hardware; and

9 (C) purchasing or leasing communications
10 capabilities necessary for clinical data access,
11 storage, and exchange.

12 (2) The term “health care provider” has the
13 same meaning given to the term “provider” in sec-
14 tion 921 of the Public Health Services Act (as
15 amended by this Act).

16 (h) TERMINATION OF GRANT AUTHORITIES.—The
17 authority of the Secretary to make grants under sub-
18 section (a) terminates upon the expiration of fiscal year
19 2011.

20 (i) MATCHING FUNDS.—

21 (1) IN GENERAL.—With respect to the costs of
22 a grant to be carried out under this section, such
23 grant may be made only if the applicant agrees to
24 make available (directly or through donations from
25 public or private entities) non-Federal contributions

1 toward such costs in an amount that is not less than
 2 50 percent of such costs (\$1 for each \$1 of Federal
 3 funds provided in the grant).

4 (2) DETERMINATION OF AMOUNTS CONTRIB-
 5 UTED.—Amounts provided by the Federal Govern-
 6 ment, or services assisted or subsidized to any sig-
 7 nificant extent by the Federal Government, may not
 8 be included in determining the amount of such non-
 9 Federal contributions.

10 **SEC. 106. AUTHORIZATION OF APPROPRIATIONS FOR**
 11 **GRANTS UNDER SECTIONS 104 AND 105.**

12 For the purpose of carrying out sections 104 and
 13 105, there are authorized to be appropriated \$25,000,000
 14 for each of fiscal years 2004 and 2005.

15 **TITLE II—MEDICAL INFORMA-**
 16 **TION TECHNOLOGY ADVI-**
 17 **SORY BOARD.**

18 **SEC. 201. MEDICAL INFORMATION TECHNOLOGY ADVISORY**
 19 **BOARD.**

20 Title XI of the Social Security Act is amended by
 21 adding at the end the following new section:

22 “MEDICAL INFORMATION TECHNOLOGY ADVISORY BOARD

23 “SEC. 1180. (a) ESTABLISHMENT.—

24 “(1) IN GENERAL.—Not later than 3 months
 25 after the date of the enactment of this section, the
 26 Secretary shall appoint an advisory board to be

1 known as the ‘Medical Information Technology Advi-
2 sory Board’ (in this section referred to as the
3 ‘MITAB’).

4 “(2) CHAIRMAN.—The Secretary shall des-
5 ignate one member as chairman. The chairman shall
6 be an individual affiliated with an organization hav-
7 ing expertise creating American National Standards
8 Institute (ANSI) accepted standards in health care
9 information technology and a member of the Na-
10 tional Committee for Vital and Health Statistics.

11 “(b) COMPOSITION.—

12 “(1) IN GENERAL.—The MITAB shall consist
13 of not more than 17 members that include—

14 “(A) experts from the fields of medical in-
15 formation, information technology, medical con-
16 tinuous quality improvement, medical records
17 security and privacy, individual and institu-
18 tional health care clinical providers, health re-
19 searchers, and health care purchasers;

20 “(B) one or more staff experts from each
21 of the following: the Centers for Medicare &
22 Medicaid Services, the Agency for Healthcare
23 Research and Quality, and the Institute of
24 Medicine of the National Academy of Sciences;

1 “(C) representatives of private organiza-
2 tions with expertise in medical infomatics;

3 “(D) a representative of a teaching hos-
4 pital; and

5 “(E) one or more representatives of the
6 health care information technology industry.

7 “(2) TERMS OF APPOINTMENT.—The term of
8 any appointment under paragraph (1) to the
9 MITAB shall be for the life of the MITAB.

10 “(3) MEETINGS.—The MITAB shall meet at
11 the call of its chairman or a majority of its mem-
12 bers.

13 “(4) VACANCIES.—A vacancy on the MITAB
14 shall be filled in the same manner in which the origi-
15 nal appointment was made not later than 30 days
16 after the MITAB is given notice of the vacancy and
17 shall not affect the power of the remaining members
18 to execute the duties of the MITAB.

19 “(5) COMPENSATION.—Members of the MITAB
20 shall receive no additional pay, allowances, or bene-
21 fits by reason of their service on the MITAB.

22 “(6) EXPENSES.—Each member of the MITAB
23 shall receive travel expenses and per diem in lieu of
24 subsistence in accordance with sections 5702 and
25 5703 of title 5, United States Code.

1 “(c) DUTIES.—

2 “(1) IN GENERAL.—The MITAB shall on an
3 ongoing basis advise, and make recommendations to,
4 the Secretary regarding medical information tech-
5 nology, including the following:

6 “(A) The best current practices in medical
7 information technology.

8 “(B) Methods for the adoption (not later
9 than 2 years after the date of the enactment of
10 this section) of a uniform health care informa-
11 tion system interface between and among old
12 and new computer systems.

13 “(C) Recommendations for health care vo-
14 cabulary, messaging, and other technology
15 standards (including a common lexicon for com-
16 puter technology) necessary to achieve the
17 interoperability of health care information sys-
18 tems for the purposes described in subpara-
19 graph (E).

20 “(D) Methods of implementing—

21 “(i) health care information tech-
22 nology interoperability standardization;
23 and

24 “(ii) records security.

1 “(E) Methods to promote information ex-
2 change among health care providers so that
3 long-term compatibility among information sys-
4 tems is maximized, in order to do one or more
5 of the following:

6 “(i) To maximize positive outcomes in
7 clinical care—

8 “(I) by providing decision sup-
9 port for diagnosis and care; and

10 “(II) by assisting in the emer-
11 gency treatment of a patient pre-
12 senting at a facility where there is no
13 medical record for the patient.

14 “(ii) To contribute to (and be con-
15 sistent with) the development of the pa-
16 tient assessment instrument provided for
17 under section 545 of the Medicare, Med-
18 icaid, and SCHIP Benefits Improvement
19 and Protection Act of 2000, and to assist
20 in minimizing the need for new and dif-
21 ferent records as patients move from pro-
22 vider to provider.

23 “(iii) To reduce or eliminate the need
24 for redundant records, paperwork, and the

1 repetitive taking of patient histories and
2 administering of tests.

3 “(iv) To minimize medical errors,
4 such as administration of contraindicated
5 drugs.

6 “(v) To provide a compatible informa-
7 tion technology architecture that facilitates
8 future quality and cost-saving needs and
9 that avoids the financing and development
10 of information technology systems that are
11 not readily compatible.

12 “(2) REPORTS.—

13 “(A) INITIAL REPORT.—No later than 18
14 months after the date of the enactment of this
15 section, the MITAB shall submit to Congress
16 and the Secretary an initial report concerning
17 the matters described in paragraph (1). The re-
18 port shall include—

19 “(i) the practices described in para-
20 graph (1)(A), including the status of
21 health care information technology stand-
22 ards being developed by private sector and
23 public-private groups;

1 “(ii) recommendations for accelerating
2 the development of common health care
3 terminology standards;

4 “(iii) recommendations for completing
5 development of health care information
6 system messaging standards; and

7 “(iv) progress toward meeting the
8 deadline described in paragraph (1)(B) for
9 adoption of methods described in such
10 paragraph.

11 “(B) SUBSEQUENT REPORTS.—During
12 each of the 2 years after the year in which the
13 report is submitted under subparagraph (A),
14 the MITAB shall submit to Congress and the
15 Secretary an annual report relating to addi-
16 tional recommendations, best practices, results
17 of information technology improvements, anal-
18 yses of private sector efforts to implement the
19 interoperability standards established in section
20 102 of the Patient Safety and Quality Improve-
21 ment Act, and such other matters as may help
22 ensure the most rapid dissemination of best
23 practices in health care information technology.

24 “(d) STAFF AND SUPPORT SERVICES.—

25 “(1) EXECUTIVE DIRECTOR.—

1 “(A) APPOINTMENT.—The Chairman shall
2 appoint an executive director of the MITAB.

3 “(B) COMPENSATION.—The executive di-
4 rector shall be paid the rate of basic pay for
5 level V of the Executive Schedule.

6 “(2) STAFF.—With the approval of the
7 MITAB, the executive director may appoint such
8 personnel as the executive director considers appro-
9 priate.

10 “(3) APPLICABILITY OF CIVIL SERVICE LAWS.—
11 The staff of the MITAB shall be appointed without
12 regard to the provisions of title 5, United States
13 Code, governing appointments in the competitive
14 service, and shall be paid without regard to the pro-
15 visions of chapter 51 and subchapter III of chapter
16 53 of such title (relating to classification and Gen-
17 eral Schedule pay rates).

18 “(4) EXPERTS AND CONSULTANTS.—With the
19 approval of the MITAB, the executive director may
20 procure temporary and intermittent services under
21 section 3109(b) of title 5, United States Code.

22 “(e) POWERS.—

23 “(1) HEARINGS AND OTHER ACTIVITIES.—For
24 the purpose of carrying out its duties, the MITAB
25 may hold such hearings and undertake such other

1 activities as the MITAB determines to be necessary
2 to carry out its duties.

3 “(2) DETAIL OF FEDERAL EMPLOYEES.—Upon
4 the request of the MITAB, the head of any Federal
5 agency is authorized to detail, without reimburse-
6 ment, any of the personnel of such agency to the
7 MITAB to assist the MITAB in carrying out its du-
8 ties. Any such detail shall not interrupt or otherwise
9 affect the civil service status or privileges of the
10 Federal employee.

11 “(3) TECHNICAL ASSISTANCE.—Upon the re-
12 quest of the MITAB, the head of a Federal agency
13 shall provide such technical assistance to the
14 MITAB as the MITAB determines to be necessary
15 to carry out its duties.

16 “(4) OBTAINING INFORMATION.—The MITAB
17 may secure directly from any Federal agency infor-
18 mation necessary to enable it to carry out its duties,
19 if the information may be disclosed under section
20 552 of title 5, United States Code. Upon request of
21 the Chairman of the MITAB, the head of such agen-
22 cy shall furnish such information to the MITAB.

23 “(f) TERMINATION.—The MITAB shall terminate 30
24 days after the date of submission of its final report under
25 subsection (e)(2)(B).

1 “(g) APPLICABILITY OF FACA.—The provisions of
2 the Federal Advisory Committee Act (5 U.S.C. App.) shall
3 apply to the MITAB.

4 “(h) FUNDING.—There are authorized to be appro-
5 priated such sums as are necessary for each fiscal year
6 to carry out this section.”.

Passed the House of Representatives March 12,
2003.

Attest:

JEFF TRANDAHL,
Clerk.